Recently, SOLO-1 trial showed that among 391 patients with newly diagnosed advanced high-grade serous or endometrioid OC, primary peritoneal cancer, or fallopian-tube cancer (or a combination thereof) with a mutation in BRCA1, BRCA2, or both who underwent randomization, the use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced OC and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with placebo during a 41 month follow-up period [4, 20, 21]. The gene discussed is BRCA1; the disease is peritoneum cancer.